Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sagimet Biosciences
Biotech
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Madrigal’s MASH drug has been approved. For the other companies with up-and-coming treatments trailing in the clinic, the question is: What now?
Annalee Armstrong
Mar 15, 2024 10:55am
Sagimet stock doubles as phase 2b MASH trial hits primary goals
Jan 22, 2024 10:30am
Sagimet's NASH drug-GLP-1 combo tops either alone for fibrosis
Nov 29, 2023 8:06pm
Apogee, Sagimet overshoot IPO expectations as they reach Nasdaq
Jul 14, 2023 8:55am
2 biotechs test icy IPO waters with $228M and $66M offerings
Jul 10, 2023 11:43am
Frazier departs Merck after 30 years—Chutes & Ladders
Oct 28, 2022 9:30am
